What is the difference between anti-obesity drugs?

Ozempic This is a well-known drug that is used for weight loss, but it is not the only one, as it also has other strong competitors. Company Lilly announced that as of July 1 will begin marketing in Spain Muñaro (tirzepatide), new medicine for control type 2 diabetes and obesity. This drug joins a list of treatments aimed at weight loss and blood glucose control. Let’s look at the differences between the main anti-obesity drugs.

Saxenda (Liraglutide)

He The first drug approved in Spain for these purposes was Saxenda (Liraglutide). Saxenda has been available in Spanish pharmacies for six years. a drug for daily injections that belongs to a group of drugs that mimic the action of the GLP-1 hormone.. This hormone reduces appetite, increases the feeling of fullness and delays gastric emptying. However, their The effectiveness is more modest compared to other drugs.achieving average weight loss 8%. This contrasts with The 16% Weight Loss Wegovy and Ozempic Can Achieveand even more with From 20% to 25% with Mujaro.

Ozempic (Semaglutide)

Ozempic from Novo Nordisk, marked a turning point in the treatment of both obesity and type 2 diabetes.. This is an injectable drug, but only requires a weekly injection. Ozempic reduces appetite and helps users choose healthier, less fatty foods. This drug is popular not only because of its effectiveness in losing weight, but also because It has been shown to be effective in controlling glucose levels when other treatments fail.

veg

Similarly, Novo Nordisk launched vegwhich is essentially the same medicine as Ozempic, but with a different name and dosage.. Introduced weekly using a pre-filled handle and specially designed to reduce weight.

Mujaro

A new competitor in the market is Mujaro. This medicine is not only acts on the GLP-1 receptor but also about GUI receiver, which increases its effectiveness and tolerability. Research has shown that Mujaro allows you to reduce weight by 22.5%, approximately 25 kg.And 96% of patients achieve weight loss of more than 5%. Moreover, it demonstrated improve body composition and in some cases almost completely reverse type 2 diabetes.

A flaw Mujaro is what In Spain it does not yet have government funding.. He Mujaro price fluctuates between 271 and 358 euros per month, depending on the dose. Wegovy is also expensive, with prices ranging from 179.from 0.89 euros to 292.03 euros per monthand it has no government funding. Meanwhile Ozempic funded just for him type 2 diabetes treatmentnot for weight loss.

All these treatments injections and they have similar side effects. stomach discomfort such as nausea, diarrhea and constipation common, but usually disappear over time and with gradual dosing. There is also risk of rebound effectwhere weight loss stops when we stop taking the medication.